TB-500: The Thymosin Beta-4 Fragment With an 8-6 PCAC Vote, Decades of Preclinical Data, and No Human Efficacy Trials

Key takeaways

• TB-500 is a synthetic 17-amino acid fragment of thymosin beta-4 (Tβ4), not the full-length protein; the FDA's own review emphasises that clinical studies of the full protein cannot be directly extrapolated to TB-500.
• The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 in favour of recommending TB-500 for the Section 503A Bulk Drug Substances List at its 23–24 July 2026 meeting — overriding staff who recommended against listing it.
• The committee vote is advisory and non-binding. Formal rulemaking, including a Notice of Proposed Rulemaking and public comment period, is required before any compounding pharmacy may lawfully use TB-500 as a bulk substance.
• As of 26 August 2026, no controlled human clinical trial has directly administered TB-500 as an investigational agent; existing Phase 2 data concern full-length thymosin beta-4 (RGN-259) in ophthalmic indications.
• TB-500 remains prohibited at all times under Section S2 of the 2026 WADA Prohibited List.
• In the UK, TB-500 holds no MHRA marketing authorisation and is not listed in any British Pharmacopoeia monograph; its supply is governed by the Medicines Act 1968 and it may only be lawfully held for bona fide research purposes.

What TB-500 is — and what it is not

TB-500 is a synthetic heptapeptide corresponding to amino acids 17–23 of thymosin beta-4 (Tβ4), a naturally occurring 43-amino acid peptide involved in actin binding, cell migration, angiogenesis, and tissue repair. The key active sequence — LKKTETQ — is acetylated at the N-terminus in the commercial synthetic form, which enhances stability and biological activity relative to the unmodified fragment.

The distinction between TB-500 and the full Tβ4 protein matters considerably, both scientifically and regulatorily. Thymosin beta-4 itself was first isolated from calf thymus tissue by Dr. Allan Goldstein and colleagues at the National Institutes of Health, with researchers noticing that the protein appeared in unusually high concentrations at wound sites, healing tendons, and post-injury muscle tissue. That observation generated decades of research into its role in cellular repair — research that, however, was primarily conducted with the full-length protein. Some closely related compounds — including full-length thymosin beta-4 (RGN-259) — have entered formal clinical trials for conditions such as dry eye disease and cardiac recovery, but TB-500 itself remains an investigational compound with no approved indication.

Proposed mechanism of action

TB-500 works by mimicking thymosin beta-4's role as a master regulator of cellular movement and tissue repair. The active LKKTETQ amino acid sequence binds to actin — the protein scaffold inside every cell — and influences how cells reshape, move, and respond to injury. More specifically, TB-500 binds G-actin (globular actin) and helps direct it to sites where the body requires cellular movement and tissue repair, with downstream effects across several healing pathways. Related laboratory work examines angiogenesis and inflammatory signalling as secondary mechanistic targets.

Researchers note, however, that these mechanisms give concrete recovery hypotheses to test, while direct TB-500 outcome studies in humans remain the missing step. Put differently, the actin-sequestration model is scientifically coherent, but its translation from preclinical models to human clinical outcomes has not yet been formally demonstrated.

State of the clinical evidence

The evidence base for TB-500 specifically — as opposed to full-length Tβ4 — is limited at human level. There are no controlled human clinical trials for TB-500; clinical research for full thymosin beta-4 is limited and indication-specific.

The most directly relevant human data concern the full-length protein in wound healing. Two small Phase 2 clinical trials provided preliminary data: in a European double-blind, placebo-controlled study (n=73), 0.03% topical TB-500 led to complete healing in approximately 25% of patients within 3 months, typically in small to moderate venous stasis ulcers. In pressure and stasis ulcers, it accelerated healing by nearly one month in some patients, but overall healing rates were not conclusively superior to control. These results — mixed and involving the full protein in topical form — are the primary human data cited in regulatory discussions.

The FDA's 2026 review found that studies submitted for wound healing used the full protein, while no human study had administered TB-500 itself. This point is not a technicality: the pharmacokinetics, bioavailability, and dose-response characteristics of a 17-amino acid fragment differ from those of a 43-amino acid protein, and cross-study extrapolation has recognised limitations.

No peer-reviewed studies have investigated the clinical safety of TB-500 specifically. Clinical trials on thymosin beta-4 indicate generally acceptable tolerability with most adverse events being mild and transient, but these data cannot be directly extrapolated to TB-500 in the absence of dedicated clinical research.

The July 2026 PCAC vote: what happened and what it means

The FDA's Pharmacy Compounding Advisory Committee met on 23–24 July 2026 at the agency's White Oak Campus in Silver Spring, Maryland, to evaluate whether seven peptides should be recommended for inclusion on the Section 503A Bulk Drug Substances List. TB-500 was among the seven, alongside BPC-157, KPV, MOTS-c, Emideltide (DSIP), Semax, and Epitalon.

Ahead of the meeting, FDA career scientists posted briefing materials concluding that the evidence does not support adding any of the seven peptides to the 503A Bulks List. The agency applied its four-factor framework — characterisation, evidence of safety, evidence of effectiveness, and clinical need — and reached negative conclusions on all seven.

The committee voted against FDA staff recommendations in six of seven cases — a notably unusual outcome. For TB-500 specifically, the vote was 8-6 in favour, with one abstention, on Day 1 of the meeting (23 July). The only compound the committee declined to recommend was Emideltide (DSIP), which failed 6-7.

The implications for procurement professionals require careful parsing:

• The 503A Bulks List is the only legal pathway for compounding pharmacies to prepare these peptides for individual patients with a physician's prescription. If a peptide is not on this list, has no USP monograph, and is not part of an FDA-approved drug, it cannot be legally compounded in the USA.
• A positive PCAC recommendation begins formal rulemaking that includes a Notice of Proposed Rulemaking, a public comment period, and a final rule. This process typically takes additional months to years to complete.
• The votes are advisory, not binding, and none of the six favourably voted compounds is currently legal to compound: the FDA still has to run rulemaking first.

Compounding pharmacies and research suppliers should not interpret the 8-6 vote as conferring any immediate change in TB-500's legal status. The FDA has not made a final decision, and current access rules remain unchanged.

Regulatory status in the US and UK

United States. TB-500 is classified as an FDA 503A Category 2 bulk drug substance; it is prohibited for use in compounded medications under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act and is not FDA-approved for any human therapeutic indication. It was removed from the Category 2 nomination list in April 2026 following the withdrawal of its original nominator, returning it to general bulk-substance status pending formal rulemaking on the PCAC recommendation. Lack of standardised manufacturing procedures and regulatory quality oversight means there is significant variability in purity, potency, sterility, and consistency among suppliers of research-grade TB-500 — a material concern for any procurement officer evaluating Certificate of Analysis documentation.

Anti-doping. TB-500 is prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) of the 2026 WADA Prohibited List. Research institutions operating with sport-adjacent populations or athlete cohorts should ensure their supply chains are properly documented to avoid inadvertent violations.

United Kingdom. TB-500 holds no MHRA marketing authorisation and does not appear in any British Pharmacopoeia compendial monograph. Under the Human Medicines Regulations 2012, supplying an unlicensed medicinal product for human use without an appropriate exemption is unlawful. Research-use supply is permissible provided it is demonstrably not for human administration and is correctly labelled as a research chemical. UK labs should note that MHRA enforcement has become more active in the peptide sector, and import shipments may be subject to Border Force examination.

Manufacturing and quality considerations for procurement

The absence of a USP monograph for TB-500 means there is no compendial standard against which batch purity can be objectively assessed. Research-procurement professionals should require at minimum:

• HPLC purity certification at ≥98% by area, with a chromatogram showing the principal peak and absence of known thymosin beta-4 degradation products.
• Mass spectrometry confirmation of the molecular weight corresponding to the LKKTETQ sequence with N-terminal acetylation (calculated MW approximately 799.9 Da for the acetylated heptapeptide).
• Endotoxin testing (LAL method) for any injectable-format product; a certificate showing <1 EU/mg is the accepted research standard.
• Chain-of-custody documentation from the peptide synthesiser to the end laboratory, particularly important given the supply-chain opacity noted by regulatory agencies.

What comes next

The PCAC vote opens the formal rulemaking track. The FDA is expected to publish a Notice of Proposed Rulemaking, after which a public comment period will follow before any final rule is issued — a process that typically takes six to twelve months at minimum. In April 2026, the FDA also indicated that another peptide-focused PCAC meeting is expected before the end of February 2027, at which additional compounds may be evaluated.

The most significant clinical unmet need for TB-500 is the absence of a direct human pharmacokinetic or efficacy study. Until a properly designed trial administers TB-500 to human subjects, characterises its absorption, half-life, and dose-response, and measures pre-specified wound-healing or tissue-repair endpoints, the regulatory and scientific position will remain one of preclinical promise without confirmatory human data.

For UK research labs procuring TB-500 for in vitro or animal-model work, the PCAC vote is background context rather than an operational trigger. Procurement decisions should continue to rest on supplier quality documentation, regulatory compliance with UK research-chemical rules, and the lab's own institutional ethical approval framework.